Aging

Do muscle strength cut-offs used to define sarcopenia affect trajectories of disability progression in basic activities of daily living in older adults?

OBJECTIVE

This study aims to analyse trajectories of disability progression in basic activities of daily living (BADLs) as a function of sarcopenia, using different cut-off points for defining low muscle strength (LMS).

METHODS

A longitudinal study included 3,328 participants from the English Longitudinal...

🗓️ 2026-08-06
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreDo muscle strength cut-offs used to define sarcopenia affect trajectories of disability progression in basic activities of daily living in older adults?

A C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Sarcopenia is a manifestation of musculoskeletal aging, yet no approved therapy is available. A major challenge is not the lack of potential interventions, but the difficulty of efficiently identifying which candidates should advance to aged-mammal validation. Sarcopenia is driven by...

🗓️ 2026-07-28
📰 Publication: Aging And Disease
Read MoreA C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Prevalence of sarcopenia and individual- and country-level risk factors in 36 countries: pooled analysis of nationally representative individual data.

BACKGROUND

Sarcopenia is an age-related condition that contributes to disability and healthcare burden worldwide. Yet cross-national evidence on prevalence and multi-level risk factors is limited.

METHODS

We pooled data from 10 nationally representative or population-based ageing studies, including 144 226 adults aged ≥50 years...

🗓️ 2026-07-23
📰 Publication: Age And Ageing
Read MorePrevalence of sarcopenia and individual- and country-level risk factors in 36 countries: pooled analysis of nationally representative individual data.

CXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

BACKGROUND

Sarcopenia is a progressive muscle-wasting condition driven in part by chronic inflammation; however, the specific inflammatory mediators that contribute to functional decline in humans and their responses to exercise remain poorly defined.

METHODS

We analyzed public ribonucleic acid (RNA) datasets to identify...

🗓️ 2026-07-23
📰 Publication: Journal Of Sport And Health Science
Read MoreCXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

Plasma Extracellular Vesicles-Derived Complement Proteins as Biomarkers of Sarcopenia Progression in Longitudinal Cohorts.

BACKGROUND

Sarcopenia is characterized by progressive loss of muscle mass, strength and physical performance, yet current diagnostic tools are limited for practical and longitudinal monitoring. Extracellular vesicles (EVs) encapsulate various biomolecules, including proteins, nucleic acids, lipids and metabolites and have emerged...

🗓️ 2026-07-21
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePlasma Extracellular Vesicles-Derived Complement Proteins as Biomarkers of Sarcopenia Progression in Longitudinal Cohorts.

Biological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

INTRODUCTION

Sarcopenia, the accelerated loss of muscle mass, strength and function with age, is associated with adverse health outcomes. DNA methylation accumulates across life and methylation clocks (which provide a measure of biological age) could potentially be used to predict individuals...

🗓️ 2026-07-19
📰 Publication: Aging Clinical And Experimental Research
Read MoreBiological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

Metabolic Syndrome as a Determinant of Bidirectional Transitions Between Frailty States: Evidence From the Whitehall II Study.

BACKGROUND

Understanding interactions between geriatric syndromes is central for promoting healthy aging. Frailty is among the most relevant, as it predicts disability, falls, hospitalization and mortality. In addition, emerging evidence also indicates that metabolic factors play a key role in the...

🗓️ 2026-07-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMetabolic Syndrome as a Determinant of Bidirectional Transitions Between Frailty States: Evidence From the Whitehall II Study.

Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

INTRODUCTION

While both frailty and sarcopenia have been linked with the Alzheimer's disease (AD) clinical phenotype, their association with AD pathophysiology is unclear. This review aimed to identify current evidence of relationships between frailty, sarcopenia and AD biomarkers.

METHODS

Four databases (Ovid MEDLINE,...

🗓️ 2026-07-08
📰 Publication: Ageing Research Reviews
Read MoreAssessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

Frailty phenotype transitions and functional improvements during a supervised exercise trial in older people with HIV: results from the HEALTH Trial.

BACKGROUND

Frailty and sarcopenia contribute to functional decline in older people with HIV (PWH), yet intervention data remain limited. We evaluated changes in frailty phenotype status, sarcopenia-related outcomes and functional performance during a supervised exercise trial and assessed associations between baseline...

🗓️ 2026-07-06
📰 Publication: Age And Ageing
Read MoreFrailty phenotype transitions and functional improvements during a supervised exercise trial in older people with HIV: results from the HEALTH Trial.

Associations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

BACKGROUND

Hospital-associated deconditioning is a contributor to secondary sarcopenia, which may be driven by prolonged hospital length of stay (LoS). This study investigated the bidirectional association of LoS and sarcopenia indices (lean soft tissue, muscle strength, physical function) in older inpatients,...

🗓️ 2026-06-25
📰 Publication: Aging Clinical And Experimental Research
Read MoreAssociations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

BACKGROUND

Sarcopenia is a chronic degenerative condition characterized by the progressive loss of muscle mass and function. Current therapeutic strategies exhibit limited therapeutic efficacy and present substantial challenges in ensuring sustained patient compliance. Although mitochondrial dysfunction is a confirmed biomarker of...

🗓️ 2026-06-18
📰 Publication: Phytomedicine
Read More3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

RNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Evidence identifies proteostasis imbalance and oxidative stress serve as fundamental pathological hallmarks of muscular atrophy, yet ring finger protein 10 (RNF10), a novel E3 ubiquitin ligase, in age-related muscular atrophy remains poorly characterized. Employing a natural aging mouse model and...

🗓️ 2026-06-18
📰 Publication: Free Radical Biology And Medicine
Read MoreRNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Muscle Ageing and Sarcopenia Study (MASS) Lifecourse: a valuable resource for understanding skeletal muscle ageing.

Advances in our understanding of the biology of skeletal muscle ageing are being made at pace, with great potential for these findings to inform the identification of novel treatments for sarcopenia. However, translation of findings from animal models to humans...

🗓️ 2026-06-15
Read MoreMuscle Ageing and Sarcopenia Study (MASS) Lifecourse: a valuable resource for understanding skeletal muscle ageing.

Muscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

BACKGROUND

Muscle-adipose aging reflects interactions between body composition changes and chronic inflammatory processes, but age-related patterns in these measures across ethnically diverse populations remain incompletely described. Understanding population-specific patterns is crucial for developing tailored prevention and intervention strategies. We aimed to...

🗓️ 2026-06-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

Exploring the role of parathyroid hormone in sarcopenia: A review.

PURPOSE OF REVIEW

Sarcopenia is a progressive, multifactorial geriatric syndrome linked to increased risk of falls, fractures, disability, frailty, and all-cause mortality. The pathophysiology of this complex syndrome remains unclear. Emerging evidence suggests that chronically elevated parathyroid hormone (PTH) concentration may...

🗓️ 2026-05-27
Read MoreExploring the role of parathyroid hormone in sarcopenia: A review.

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Sarcopenia is an age-related skeletal muscle disorder characterized by reduced muscle mass, strength, and physical performance, as well as increased risk of disability, hospitalization, and mortality. Emerging evidence suggests that gut microbiota alterations may contribute to muscle decline via a...

🗓️ 2026-05-27
Read MoreThe Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!